LT.Swing trade!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More on Dr Brian Stedman; Southampton – The world’s leading Chemosaturation Therapy Centre, treating ocular melanoma liver metastases
28-Mar-2017 The team at Spire Southampton Hospital has successfully completed its 100th chemosaturation therapy procedure.
Patient Brian Carney receives his 7th chemosaturation therapy procedure
“I’ve had three years I wouldn’t have had” states patient Mr Brian Carney
Southampton based team helps increase life expectancy for patients with metastatic liver cancer from ocular melanoma(OM) [1]
In 50%[2] of patients with OM, the tumour spreads to their liver and this becomes the main or life-limiting component of their disease
As part of a holistic approach to treating cancer, the liver-directed high dose chemotherapy, known as chemosaturation therapy is delivered by a multi-disciplinary team at Spire Southampton Hospital and at Southampton University Hospital
World’s leading centre
Southampton is the leading chemosaturation therapy centre in the world with the highest number of recorded treatments in ocular melanoma liver metastases and among the best published evidence of clinical benefit to the patients.
The Southampton team, led by Dr Brian Stedman, consultant interventional radiologist at Spire Southampton Hospital, has just carried out the 100th chemosaturation therapy procedure– a treatment helping extend the life expectancy of patients with liver cancer from metastatic ocular melanoma from a few months to years.
Patients travel from Singapore, Israel, Ireland, USA and across the UK to the Southampton team based at Spire Southampton Hospital and The University Hospital Southampton.
The treatment
Chemosaturation therapy allows doctors to administer an anti-cancer drug at a higher concentration level than is possible in systemic chemotherapy because the liver is isolated from the rest of the body. By delivering this drug to the entire liver, treatment is administered to potentially both visible tumours and undetected micro tumours.
The procedure involves using two small balloons to divert blood past the liver, while delivering drugs directly into the organ.
A technology called chemosaturation therapy developed by Delcath Systems is a liver specific chemotherapy delivery system. It is designed to treat cancers in the liver by delivering concentrated doses of an anti-cancer drug directly to the liver while potentially allowing for manageable side effects preserving the liver and potentially extending survival.
Once the drug has been delivered, blood from the liver is drained from the patient and processed through a filtration machine to reduce toxicity, before being returned to the patient via the jugular vein.
The patient
Mr Brian Carney, a retired businessman from West Yorkshire, was diagnosed with OM in 2005. He has undergone his seventh chemosaturation therapy, more than anyone else in the UK.
He explains:
“Since 2013 I’ve had several liver resections, immunotherapy treatments and seven rounds of chemosaturation therapy. It has been over three years since my cancer spread (metastasised), but at the moment I am well, although I have regular scans and I am prepared to undergo more treatment if necessary. During the intervening period I have generally enjoyed pretty good health, travelled extensively and seen the birth of my two grandchildren. The combination of surgery, chemosaturation therapy and the complementary treatments offered at Southampton has been a great success as far as I am concerned.
“Few oncology centres have much experience of treating OM as it is so rare, but I was lucky enough to be referred to Dr Brian Stedman at Spire Southampton Hospital, where I have been treated for over three years. Every time I go to the hospital it is like meeting old friends who happen to be experts; including nurses, therapists and doctors.
“My experience is that Professor Christian Ottensmeier at Southampton General Hospital and Dr Stedman and his team have significantly improved the clinical procedure over the last few years. After my first procedure I felt tired and weak for a couple of weeks and I needed frequent blood tests for several weeks afterwards. That compares with my fourth procedure when I flew directly from Southampton to Glasgow to attend an open air ACDC concert, followed two days later by a Fleetwood Mac concert. It may not sound anything very much but, as a patient, the difference in recovery has improved out of all recognition. I have tried to maintain the trend - I celebrated my 7th chemosaturation therapy with two separate Black Sabbath concerts.
“The advancements in the treatment of liver cancer are rapid and I hope to keep going with this treatment until liver cancer is seen as a chronic disease rather than a dangerous and life limiting form of cancer. Brian Stedman and Sanjay Gupta, the Critical Care Consultant, have worked wonders in minimising the time required in hospital and the recovery time for patients.”
The consultant, Dr Brian Stedman
As Dr Stedman explains: “Chemosaturation therapy involves three basis steps: 1) Isolation 2) Saturation 3) Filtration. In essence we are cutting off the liver from the rest of the body to soak it in a high dose of a drug and then filtering the blood almost completely clean before returning it to the body.
“This treatment has changed the way we treat ocular melanoma liver metastases. We know the treatment works and as a team, we have focussed on patient safety, leading to a very positive outcomes and improved quality of life for our patients.”
[1] Uveal Melanoma UK National Guidelines, P. Nathan et al. / European Journal of Cancer 51 (2015) 2404–2412
[2] http://delcath.com/reuters-news/?id=2247663
[3] www.melanomauk.org.u
To book an appointment with Dr Stedman please contact Debbie Brooks Tel: 023 80 764352 or visit: www.spirehealthcare.com/consultant-profiles/dr-brian-stedman-c4129567/ http://www.privatehealth.co.uk/news/southampton-%E2%80%93-world%E2%80%99s-leading-chemosaturation-therapy-centre-treating-ocular-melanoma-liver/
More on DR Brian Stedman! "Recently I introduced delcath (isolated liver perfusion service) the first and only in the UK and only one of a handful in the world. With these new tools I hope to treat liver tumours without the morbidity associated with conventional treatments.")! https://finder.bupa.co.uk/Consultant/view/72976/dr_brian_stedman
Dr Brian Stedman? @interoncologist Mar 29
On $DCTH
" #delcath 100 cases - great outcomes and no major complications"!! https://twitter.com/interoncologist?lang=en
Short Squeeze Alerts
$DCTH (Delcath Systems, Inc.) could become a potential short squeeze opportunity with significant short interest of 185.86%. http://speculatingstocks.com/pulse/stock/DCTH/
DCTH Percent of Float Short 185.86% Percent of Float Short!! http://speculatingstocks.com/stockcomparison/versus.php?stock1=1954&stock2=20988
Date Open High Low Close Adj Close* Volume
Apr 04, 2017 0.09 0.09 0.08 0.08 0.08 12,508,600 --https://finance.yahoo.com/quote/DCTH?p=DCTH
Oh good,thank you!
What was yesterdays volume?
Apr 04 0.08 0.09 0.08 Volume 12,508,600!!! /3,121,694 = 24.96%
% of Vol Shorted 24.96%
Apr 04 0.08 0.09 0.08 12,508,600 3,121,694 http://nakedshortreport.com/?index=DCTH
The Technical Chart For Delcath Systems, Inc. (DCTH) Has Spoken
By Mack Tyler - April 4, 2017 Delcath Systems, Inc. (DCTH) has created a compelling message for traders in the most recent trading. That message has grown stronger as the technical chart setup has developed into a more composite picture for the stock. This is the breakdown as we see it. Contrary to popular belief, ignorance is not bliss. What you don’t know can actually harm you; and if you are a day trader, $1 worth of ignorance could potentially cost you $100 in real wealth. Traders that succeed know this; which is why many don’t take on any trade unless they listen intently to what the technical chart has to say.
The 50 and 200 SMAs for DCTH have created a marked trend which is now helping traders to make solid decisions regarding the stock. It’s a trend that is now unmistakable. Based on the trend levels presented by both indicators, the overall sentiment towards DCTH is best described as bearish. This trend has created a unified opinion across the trading floor and it is clear that the overall outlook for the stock is now established as negative. But it’s not just the outlook that’s being affected for the stock. Thanks to the consolidated opinion on DCTH, activity has also seen a pronounced trend. Under current sentiments the volume activity and subsequent trend has created a strong outlook from buyers and sellers. Sentiments have a tendency to either weaken or strengthen as other technical factors begin to influence overall outlook. It’s interesting to see how things are playing out for DCTH. It is unsurprising in the case of DCTH, that the current trend has created some enthusiasm among traders regarding the stock. In terms of consistency, it is clear that both the 50 and 200 SMAs have done their job in bring traders the overall trend-picture currently being seen for DCTH.
There is of course more to the tale than just what the SMAs have presented. For those added details, we can take a look at the Relative strength indicator (RSI) and Stochastic measures, both of which give deeper insights into the overall sentiment of buyers and sellers. SMAs will tell alert you to price direction, but when it comes to judging what buyers and sellers are doing, few indicators are better than RSI and the Stochastic. It as this level of technical data that a trader can determine whether a stock is currently overbought is oversold. The current picture for DCTH is of course very telling based on these two additional measures. Based on current readings, DCTH’s 14-day RSI is 26.85%. Taken on the standard scale of measurement for RSI, this suggests that DCTH is currently oversold, suggesting that the stock may have hit a floor and could potentially see an uptick. The stochastic reading offers another solid measure of whether the stock is either overbought, or oversold. In the case of DCTH, Stochastic readings gathered over the last 30 days have created a score of 11.43%. This suggests DCTH is oversold at current levels.
The best strategy for using technical analysis is of course to layer on as many indicators as can fit within a singular structure – a point of view, if you like. The above indicators really start to shine when you boost them by adding other indicators into the mix. By this point in the analysis of DCTH, it is clear that other technical indicators are saying essentially the same things. Specifically the -0.06 has birthed a negative overall sentiment when measured over the previous 30 days or so of trading. Over the longer-term DCTH has underperform the S&P 500 by -115.42. This has, unsurprisingly, created higher volatility levels when compared with similar stocks of the same grade and class. Historical volatility is no less consistent. The historical volatility picture for DCTH is shown in the reading of 111.65%. DCTH has clearly shown its full hand by the overall input of these technical indicators. But there is one final measure that when added to the already rich mix, shows in full color what DCTH is doing. The indicator is the Average True Range, and based on the current 30 reading, DCTH is certainly worth paying attention to.
DCTH couldn’t be clearer in terms of the kind of action required in light of the picture shown by its technical indicators.
http://nystocknews.com/2017/04/04/the-technical-chart-for-delcath-systems-inc-dcth-has-spoken-2/
We’re Always Looking
Delcath never stops looking for talented people to add to our team. Send us your resume, and our recruiting team will contact you if we have a position that matches your qualifications.
APPLY NOW http://delcath.com/careers
$DCTH After hours 178,625 $ .084 High!
(17:56:26 PM) http://www.nasdaq.com/symbol/dcth/after-hours
Delcath Systems, Inc. (DCTH) Short Interest Update
Posted by Carolyn Dwyer on Apr 2nd, 2017 Delcath Systems, Inc. (NASDAQ:DCTH) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,711,374 shares, a growth of 120.2% from the February 28th total of 1,231,437 shares. Currently, 6.8% of the shares of the stock are sold short. Based on an average daily volume of 7,759,261 shares, the short-interest ratio is presently 0.3 days.
An institutional investor recently raised its position in Delcath Systems stock. Renaissance Technologies LLC boosted its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 167.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,128 shares of the medical device company’s stock after buying an additional 100,214 shares during the period. Renaissance Technologies LLC owned about 7.29% of Delcath Systems worth $147,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.66% of the company’s stock.
Delcath Systems (NASDAQ:DCTH) opened at 0.09 on Friday. Delcath Systems has a 52-week low of $0.08 and a 52-week high of $6.88. The firm’s market cap is $360622.41. The company has a 50-day moving average of $0.13 and a 200 day moving average of $1.37. https://www.com-unik.info/2017/04/02/delcath-systems-inc-dcth-short-interest-update.html
Anybody else hear of this Rumor? (Dr ND.
"AGIO will announcement partner with Delcath Systems, Inc. (DCTH)")!! Source from Yahoo DCTH conversation board!
March 31, 2017 Its time to give a fresh look to Delcath Systems, Inc. (DCTH) and U.S. Bancorp (USB) Shares of Delcath Systems, Inc. (NASDAQ:DCTH) observed rebound of 13.52% since bottoming out at $0.08 on Mar. 30, 2017. Meanwhile, due to an ongoing pressure which caused a decline of almost -2.81% in the past five days, the stock price is now down -90.6% so far on the year — still in weak territory. In this case, shares are down -99.92% from $6.85 , the 52-week high touched on May. 20, 2016, but are collecting gains at -99.88% for the past 12 months.
Is It Worth the Risk?
Brokerage houses, on average, are recommending investors to buy Delcath Systems, Inc. (DCTH)’s shares projecting a $16 target price. What do this target means? Price targets reflect what the analyst believes a stock will be worth four quarters into the future. Are investors supposed to sell when the stock hits the target? Price targets frequently change, depending on the outlook for a company’s earnings. Sometimes it may seem like it, but analysts don’t just pull their price targets out of thin air. Typically, they estimate what the company’s earnings and cash flow will be for the next couple of years, and then apply a ratio – such as a price-to-earnings ratio – to those estimates to determine what the future stock price should theoretically be.
http://www.usacommercedaily.com/2017/03/31/its-time-to-give-a-fresh-look-to-delcath-systems-inc-dcth-and-u-s-bancorp-usb/
MAR 30, 2017-Notable Stock For Under $5: Delcath Systems, Inc. (NASDAQ:DCTH) Investors interested in stocks under $5 should take a look at Delcath Systems, Inc. (NASDAQ:DCTH). The stock has gained quite a bit of attention of late and here we’ll take a look at the technicals at a glance. In recent trading activity, company stock has moved 0.00% touching the price of $0.09. Moving forward, the investment community will be watching to see if shares can gain some positive momentum.
Sometimes the stock market can be very confusing, even for the most seasoned investors. Even when expectations are met as predicted, the market may decide to move otherwise. This can cause uncertainty and second guessing. Keeping up with historical data as well as short-term and long-term trends may be very helpful. Over the past week, Delcath Systems, Inc. (NASDAQ:DCTH) shares have performed -8.08%. Pushing back over the last quarter, shares are -91.44%. Looking at stock performance for the past six months, shares are -97.60%. Since the start of the calendar year, shares have performed -90.60% .Let’s take a quick look at some possible support and resistence levels for the stock. According to a recent spotcheck, company Delcath Systems, Inc. (NASDAQ:DCTH) have been seen trading -87.64% away from the 50- day high. On the opposite end, shares have been trading 13.52% away from the 50-day low price. Taking a wider perspective, shares have been recently trading -99.92% off the 52-week high and 13.52% away from the 52-week low.
Of course, there is no easy answer to solving the tough question of how to best approach the stock market, especially when dealing with a turbulent investing climate. There are many different schools of thought when it comes to trading equities. Investors may have to first asses their appetite for risk in order to form a solid platform on which to construct a legitimate strategy. Does one run with the bulls and roar with the bears? Do they go against the grain and form a contrarian investing plan? The abundance of information with relatively easy access has made the road a bit smoother to walk for novice investors. Making the transition to the next level is where the champions are able to separate themselves from the pretenders.
https://morganleader.com/notable-stock-for-under-5-delcath-systems-inc-nasdaqdcth/
Wednesday, March 29. IGV 3 Improves Support for PacBio Long Reads
http://www.pacb.com/blog/igv-3-improves-support-pacbio-long-reads/
Tuesday, 28 Mar 2017 11:03 AM Delcath Systems Inc (NASDAQ:DCTH) Just Confirmed A Clear Pathway To Approval!! https://www.insiderfinancial.com/delcath-systems-inc-nasdaqdcth-just-confirmed-a-clear-pathway-to-approval/120414/
From the CEO of Delcath,JENNIFER SIMPSON MARCH 28, 2017
https://www.statnews.com/2017/03/28/cancer-treatment-quality-of-life/?platform=hootsuite
Volume Short Volume % of Vol Shorted
Mar 27 0.10 0.11 0.09 27,168,900 3,725,532 Lowest % in a month(13.71%)!!!! http://nakedshortreport.com/?index=DCTH
Your welcome Shub!
PacBio sues Oxford Nanopore for patent infringement
BY PHILLIP BROADWITH23 MARCH 2017 Firms spar over single-molecule gene sequencing technology
Gene sequencing firm Pacific Biosciences is suing rival Oxford Nanopore Technologies for patent infringement, after successfully filing a broad patent on nanopore sequencing technology.
PacBio claims that Oxford Nanopore’s MinIon and PromethIon sequencers – which use protein-based pores to electronically read nucleic acid sequences – infringe US patent 9546400, granted to PacBio in January 2017. PacBio’s own sequencers employ its Single Molecule Real Time (SMRT) sequencing technology, in which sequences are determined by synthesising complementary DNA strands inside nanosized ‘waveguide’ wells.
‘We believe this is another frivolous lawsuit brought by a competitor nervous about our superior technology,’ said Oxford Nanopore’s chief executive, Gordon Sanghera in a statement. The company was sued for patent infringement by sequencing heavyweight Illumina in 2016, but settled the dispute by switching to a different pore protein.
https://www.chemistryworld.com/news/pacbio-sues-oxford-nanopore-for-patent-infringement/3007010.article
The Correct volume was 22,072,005,not 6,858,880. Short volume was 3,837,663 So 55.95% is incorrect! If you correct the volume,it would be around 18%!
Daily Short Report http://otcshortreport.com/?index=GBLX&action=view
Daily Naked Short Report http://nakedshortreport.com/?index=PACB
Daily Short Report http://otcshortreport.com/?index=NMUS&action=view
Todays Short interest activity. % of Vol Shorted 55.95%
!!! http://nakedshortreport.com/?index=DCTH
Tuesday, March 21, 2017
New Goat Genome Assembly Breaks Continuity Record, Expands Breeding Tool Efforts to produce a reference-grade goat genome assembly for improved breeding programs have paid off. A new Nature Genetics publication reports a high-quality, highly contiguous assembly that can be used to develop genotyping tools for quick, reliable analysis of traits such as milk and meat quality or adaptation to harsh environments. The program also offers a look at how different scaffolding approaches perform with SMRT Sequencing data.
“Single-molecule sequencing and chromatin conformation capture enable de novo reference assembly of the domestic goat genome” comes from lead authors Derek Bickhart, Benjamin Rosen, and Sergey Koren; senior author Tim Smith; and collaborators. The large team of scientists is affiliated with the USDA Agricultural Research Service, National Human Genome Research Institute, the University of Washington, and many other organizations.
The project was motivated by a clear need to develop methods for high-quality livestock genome assemblies to benefit breeding communities. Goat offers a particular boost to developing countries, where these animals are a primary source of textile fiber, milk, and meat. “A finished, accurate reference genome is essential for advanced genomic selection of productive traits and gene editing in agriculturally relevant plant and animal species,” the scientists report. Previous efforts to sequence the goat genome with short reads resulted in a highly fragmented assembly that could not resolve repetitive and other challenging regions. For this work, the team analyzed the genome of a highly homozygous male San Clemente goat (Capra hircus) using a number of technologies.
They chose SMRT Sequencing because its long reads could characterize even the most difficult genomic regions. “Initial assembly of the PacBio data alone resulted in a contig NG50 … of 3.8 Mb,” the team reports. PacBio contigs were then connected with optical mapping and Hi-C data to create extremely long scaffolds in the final 2.92 Gb assembly. “These combined technologies produced what is, to our knowledge, the most continuous de novo mammalian assembly to date, with chromosome-length scaffolds and only 649 gaps,” they write. The assembly is 400 times more continuous than the previous short-read assembly.
To learn more about how these technologies complement each other, the scientists analyzed results from optical mapping and Hi-C data separately. They found that Hi-C data yielded a tenth the number of scaffolds that optical mapping did, but it led to more misoriented contigs, which were correlated with restriction site density. “Ultimately, we found that sequential scaffolding with optical mapping data followed by Hi-C data yielded an assembly with the highest continuity and best agreement with the [radiation hybrid] map,” the team reports, noting that this approach is significantly less expensive than generating a short-read draft genome assembly and manually finishing it to high quality.
The final assembly includes notoriously difficult regions, such as centromeric DNA and the Y chromosome. Two chromosomes appear to be completely assembled, and two others seem to include “the elusive p arm,” Bickhart et al. write.
Of course, since the scientists were focused on building a resource that would help breeding programs, they also assessed its potential impact in that space. “Chromosome-scale continuity of the ARS1 assembly was found to have appreciable positive impact on genetic marker order for the existing C. hircus 52K SNP chip3,” they report.
Going forward, the team hopes to generate a phased diploid assembly for C. hircus. http://www.pacb.com/blog/new-goat-genome-assembly-breaks-continuity-record-expands-breeding-tools/
Delcath Systems, Inc. (NASDAQ:DCTH) will report its next earnings on Mar 20 – Mar 24 (Est.). https://www.newsoracle.com/2017/02/02/what-do-analysts-suggest-for-delcath-systems-inc-nasdaqdcth/
I`m in,I got my Lotto Ticket! ( Delcath believes it has sufficient capital to fund its operating activities through the end of 2017.)!
From Press Release: Delcath Announces Third Quarter Financial Results
7:30 am ET November 11, 2016 (Dow Jones)
Your welcome!
March 15, 2017 at 1:16 pm-- Cannabis Panels Demonstrate Growing Appeal to Institutional Investors! The 29th annual ROTH Conference, which is sponsored by Roth Capital Partners. The panel on the 14th, which was moderated by Ted Roth, President of ROTH Capital, and also included Christopher Barry of Dorsey & Whitney, Scott Ginsburg of MM Acquisition Co, LLC, Alan Gold of Innovative Industrial Properties (NYSE: IIPR) and Dr. Brian Murphy of Nemus Bioscience (OTC: NMUS). Each of the panelists gave a brief summary of their company’s involvement in the industry before Roth asked a few questions and then the audience participated.DR.Murphy, who serves as CEO and Chief Medical Officer(OTC NMUS), is working with Albany Molecular Research (NASDAQ: AMRI) for synthetic cannabinoid production and with Teewinot Life Sciences for biosynthetic cannabinoid production. The company also works with the University of Mississippi to develop IP and employs a variety of drug delivery devices. Its areas of focus include glaucoma, MRSA, chemotherapy-induced nausea and vomiting (CINV) and chemotherapy-induced peripheral neuropathy (CIPN). Murphy, who has been involved previously with three biotech startups, made the case for why he expects the industry will shift towards synthetics over time. https://www.newcannabisventures.com/roth-conference-cannabis-panels-demonstrate-growing-appeal-to-institutional-investors/
Rectal Marijuana Is More Effective Than Smoking Joints: Doctor! http://www.huffingtonpost.ca/2017/03/05/rectal-marijuana_n_15178784.html
Swift Biosciences Launches Novel Long-Insert Library Kit to Improve Data Quality on PacBio Sequencing Platforms
Published on February 14, 2017 https://360wisenews.com/2017/02/14/swift-biosciences-launches-novel-long-insert-library-kit-improve-data-quality-pacbio-sequencing-platforms/?utm_source=ReviveOldPost&utm_medium=social&utm_campaign=ReviveOldPost
PATENT CITATIONS
Cited Patent Filing date Publication date Applicant Title
US5389375 * May 21, 1993 Feb 14, 1995 University Of Mississippi Stable suppository formulations effecting bioavailability of ?9 -thc
US6008383 * Oct 26, 1998 Dec 28, 1999 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
$NMUS Drug- NB1222 is a homerun with suppository delivery. Long time in the making, first patent filed in 2009 for formulation.
https://www.google.com/patents/US20110275555
Thanks for the link!
Yes,with CNN (fake news) it makes me a little suspicious??!! http://longlivehealthtip.online/breaking-news-u-s-govt-will-legalize-marijuana-on-march-15/